Percutaneous Coronary Intervention (PCI)
Major adverse cardiovascular events were not reduced in patients with acute coronary syndrome undergoing planned percutaneous coronary intervention when given 2 loading doses of atorvastatin.
Aim of study was to determine whether treatment with percutaneous coronary intervention or coronary artery bypass grafting leads to improved outcomes in patients with diabetes, coronary artery disease, and left ventricular dysfunction.
The smartphone heart rate monitoring application had higher diagnostic accuracy compared with standard physical examination for determining ulnar artery patency prior to radial access.
Acute myocardial infarction 30-day mortality was lower during Transcatheter Cardiovascular Therapeutics meeting dates.
Abnormal glucose metabolism may be present in patients with undetected diabetes after percutaneous coronary intervention.
In patients with diabetes, multivessel coronary artery disease, and left ventricular dysfunction, coronary artery bypass grafting was associated with a reduction in major adverse cardiac and cerebrovascular events and mortality.
A quality improvement intervention can reduce inefficiencies in the cardiac catheterization lab.
Percutaneous closure of patent foramen ovale is not associated with a reduction in migraine headaches in patients with and without aura.
Compliance with guideline-directed medical therapy is low, but remains higher in PCI than in CABG.
Percutaneous coronary intervention is associated with increased rates of adverse outcomes compared with CABG in patients with 3-vessel CAD.
Patients with multivessel coronary artery disease and diabetes may benefit more from coronary artery bypass grafting surgery vs percutaneous coronary intervention.
Use of transradial access for STEMI percutaneous coronary intervention increased from 2009 to 2015.
Percutaneous coronary intervention does not increase exercise time more than a placebo procedure in patients with angina and severe coronary stenosis.
Alternative antiplatelet therapy after percutaneous coronary intervention in patients with a CYP2C19 loss-of-function allele may have lower risk of MACE compared to clopidogrel.
A substudy analyzed whether PCI outcomes using second generation drug eluting stents were comparable to CABG in patients with low or intermediated complexity left main coronary artery disease.
Women and minorities undergoing PCI with everolimus-eluting stents have a risk of MACE similar to that of white men.
Vitamin D did not produce a substantial preventive effect on cardiac injury during percutaneous coronary intervention.
For patients with atrial fibrillation who undergo percutaneous coronary intervention, the risk of bleeding is lower with dual therapy vs triple therapy.
In patients undergoing percutaneous coronary intervention for either STEMI or NSTEMI, bivalirudin and heparin produce similar outcomes.
Coronary artery bypass grafting yielded better outcomes in patients with type 1 diabetes who had multivessel disease compared with percutaneous coronary intervention.
Coronary computed tomography angiography is an accurate method of assessing angiographic outcomes after bioresorbable vascular scaffold implantation.
Sildenafil-coated stents may help reduce clots.
Gender has no effect on the outcome of acute coronary syndrome patients undergoing percutaneous coronary intervention receiving clopidogrel, prasugrel, or ticagrelor.
Patients with HbA1c levels had lower 7-year incidence of major adverse cardiac and cerebrovascular events compared with patients with higher HbA1c levels.
Both iFR and FFR groups experienced similar rates of composite nonfatal myocardial infarction, unplanned revascularization, or all-cause death within 1 year post-procedure.
Researchers found similar rates of target-vessel failure in both scaffold and stent percutaneous coronary intervention (PCI).
Revised coronary revascularization criteria rated whether coronary interventions are appropriate in tables organized according to practice patterns.
Researchers found that same-day discharge in PCI for non-ST-segment elevation acute coronary syndromes.
A longer wait between administration of antiplatelet therapy and primary percutaneous intervention has been linked to improved coronary reperfusion.
Under scrutiny, incidence of PCI in New York state decreased from 18.2% to 10.6% between 2010-2014.
The Cardiology Advisor Articles
- The Mounting Evidence Against Electronic Cigarette Use
- Entresto Significantly Improves Physical, Social Activity in Heart Failure Patients
- Nonpsychotic Cannabinoids in Hypertension: Benefits and Harms
- ACC and AHA Release 2018 Quality Measures for Cardiac Rehabilitation
- Unique Vit B3 Formulation May Improve Blood Pressure, CV Health
- AHA: Assessment and Promotion of Physical Activity for CVD Prevention
- Benefits of Targeted Pharmacologic Therapy in PAH and Distal CTEPH
- Transcatheter vs Surgical Aortic Valve Replacement in COPD
- Breathing New Life Into COPD and Asthma Therapy With Statins
- ACP: Position Paper Recommends Solutions to Close Gender Equity Gap